Brent Fraser is CADTH Vice-President, Pharmaceutical Reviews, with responsibility for the CADTH drug products and services including the CADTH Common Drug Review (CDR), the pan-Canadian Oncology Drug Review (pCODR).
Brent is dedicated to building a team-based, client-oriented culture that values leadership, excellence, collaboration, and responsiveness. He champions customer service, business discipline, and ongoing process improvement, and he challenges his team to deliver high-quality, relevant, and timely assessments of drugs using the best available science, tools, and methodologies.
Brent is known for his strength as a thoughtful, listening, and collaborative leader who is adept at translating evidence into recommendations and actions. He combines a pharmacist’s appreciation for the clinical and human implications of his work with almost two decades of strategic experience within the largest public drug plan in the country.
Prior to joining CADTH in 2015, Brent held a variety of positions within the Ontario Public Drug Programs, where he was a key leader in the development of a pan-Canadian approach to pharmaceutical negotiations. Prior to that he was a pharmacist at the Hospital for Sick Children in Toronto.
Day 1: Oct 6, 2020
Evaluate the Impact of CADTH’s New Review Requirements and Advisory Committee
Earlier this year, CADTH introduced new submission review requirements and a merger of the Drug Policy and pCODR Advisory Committees. Understand the impact of these changes and adapt your submissions to be reviewed expediently. Source intelligence to:
- Better understand the information requirements for both CDR and pCODR under this new advisory structure
- Adopt best practices to better manage your product submissions under the revised process
- Avoid pitfalls in your submission process with insight on what are the common mistakes made by others
Position your product to successfully navigate new HTA review requirements
Day 2: Oct 7, 2020